In vitro exposure to peptidic delta opioid receptor antagonists results in limited immunosuppression

Neuropeptides

Volumn 31, Issue 1, 1997, Pages 89-93

  House, R V ^a   Thomas, P T ^a   Bhargava, H N ^b  

^a IIT RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DELTA OPIATE RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; OPIATE ANTAGONIST; TIPP; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ANIMALIA;

EID: 0031058302     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(97)90026-3     Document Type: Article

References (13)

1. Carr D J J, DeCosta B R, Kim C-H et al. Opioid receptors on cells of the immune system: evidence for δ- and κ-classes. J Endocrinol 1989; 122: 161-168.
2. Caroleo M C, Arbitrio M, Melchiorri D, Nisticò G. A reappraisal of the role of the various opioid receptor subtypes in cell-mediated immunity. Neuroimmunomodulation 1994; 1: 141-147.
3. House R V, Thomas P T, Bhargava H N. A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides. Peptides 1996; 14: 75-81.
4. Mazumder M C, Nath I, Dhar M M. Immunomodulation of human T-cell responses with receptor selective enkephalins. Immunol Lett 1993; 35: 33-38.
5. Rogers T J, Taub D D, Eisenstein T K, Geller E B, Adler M W. Immunomodulatory activity of kappa-, mu- and delta-selective opioid compounds. NIDA Res Monogr 1991; 105: 82-88.
6. Arakawa K, Akami T, Okamoto M et al. Immunosuppressive effect of δ-opioid receptor antagonist on xenogeneic mixed lymphocyte response. Transplant Proc 1992; 24: 696-697.
7. Arakawa K, Akami T, Okamoto M et al. Immunosuppression by delta opioid receptor antagonist. Transplant Proc 1993; 25: 738-740.
8. Gillis S, Perm M M, Ou W, Smith K A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978; 120: 2027-2032.
9. Hu-Li J, Ohara J, Watson C, Tsang W, Paul W E. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol 1989; 142: 800-807.
10. 2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 1986; 83: 9679-9683.
11. House R V, Thomas P T, Kozak J T, Bhargava H N. Suppression of immune function by non-peptidic delta opioid receptor antagonists. Neurosci Lett 1995; 198: 119-122.
12. Radulovíc J, Jankovíc B D. Opposing activities of brain opioid receptors in the regulation of humoral and cell-mediated immune responses in the rat. Brain Res 1994; 661: 189-195.
13. Cheido M A, Idova G V. Participation of opiate δ-receptors in immunomodulation. Neurosci Behav Physiol 1994; 24: 479-482.